Tumor-penetrating Peptide LyP-1 Enhance Efficacy of Radiotherapy by Reversing Suppressive Immune Microenvironment-Reference-Cited by-同舟云学术

Tumor-penetrating Peptide LyP-1 Enhance Efficacy of Radiotherapy by Reversing Suppressive Immune Microenvironment

Published:2023-08-21 Issue:4 Volume:200 Page:
ISSN:0033-7587
Container-title:Radiation Research
language:
Short-container-title:Radiation Research

Author:

Shi Tianyu¹,Chen Chunru²,Liu Jun³,Sun Mengna¹,Meng Fanyan²

Affiliation:

1. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China

2. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China

3. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Publisher

Radiation Research Society

Subject

Radiology, Nuclear Medicine and imaging,Radiation,Biophysics

Link

https://meridian.allenpress.com/radiation-research/article-pdf/doi/10.1667/RADE-23-00053.1/3251181/10.1667_rade-23-00053.1.pdf

Reference21 articles.

1. A Maity, WG McKenna, RJ Muschel, "Radiother Oncol." 31, "The molecular basis for cell cycle delays following ionizing radiation: a review." 1 (1994)

2. DI. Gabrilovich, "Cancer Immunol Res." 5, "Myeloid-derived suppressor cells." 3 (2017)

3. MW Dewhirst, Y Cao, B Moeller, "Nat Rev Cancer." 8, "Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response." 425 (2008)

4. L Meng, Y Cheng, X Tong, et al. "ACS Nano." 12, "Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects." 8308 (2018)

5. NS Bayin, L Ma, DG Placantonakis, et al. "Methods Mol Biol." 1741, "Evaluation of Radioresponse and Radiosensitizers in Glioblastoma Organotypic Cultures." 171 (2018)